Roivant Sciences Ltd (ROIV) - Total Liabilities
Based on the latest financial reports, Roivant Sciences Ltd (ROIV) has total liabilities worth $251.14 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Roivant Sciences Ltd long-term investment allocation to see how much of total assets are deployed in long-term investments.
Roivant Sciences Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how Roivant Sciences Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Roivant Sciences Ltd.
Roivant Sciences Ltd Competitors by Total Liabilities
The table below lists competitors of Roivant Sciences Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Partners Group Holding AG
SW:PGHN
|
Switzerland | CHF4.51 Billion |
|
Telefonica Brasil SA ADR
NYSE:VIV
|
USA | $63.21 Billion |
|
Coeur Mining Inc
NYSE:CDE
|
USA | $4.79 Billion |
|
NN Group NV
AS:NN
|
Netherlands | €183.76 Billion |
|
Raiffeisen Bank International AG
VI:RBI
|
Austria | €200.18 Billion |
|
Shenzhen Inovance Tech
SHE:300124
|
China | CN¥31.70 Billion |
|
Accelink Technologies Co Ltd
SHE:002281
|
China | CN¥7.88 Billion |
|
FUJIFILM HDGS CORP. ADR 1
F:FJIA
|
Germany | €2.21 Trillion |
Liability Composition Analysis (2019–2025)
This chart breaks down Roivant Sciences Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Roivant Sciences Ltd balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 30.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Roivant Sciences Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Roivant Sciences Ltd (2019–2025)
The table below shows the annual total liabilities of Roivant Sciences Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $249.74 Million | -67.73% |
| 2024-03-31 | $773.95 Million | -1.03% |
| 2023-03-31 | $782.02 Million | +49.33% |
| 2022-03-31 | $523.70 Million | -0.76% |
| 2021-03-31 | $527.69 Million | +43.25% |
| 2020-03-31 | $368.36 Million | -18.24% |
| 2019-03-31 | $450.51 Million | -- |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more